Karl R Dahnke from 441 Sheets Dr, Carmel, IN 46032, age 63

view source

Location:

5160 Rocky Cay Ct, Carmel, IN 46033

Industry:

Pharmaceuticals

Work:

Eli Lilly and Company
Research Chemist

Education:

The Ohio State University 1987 - 1993
PhD, Chemistry

Treatment Of Mastitis
view source
US Patent:

6369049, Apr 9, 2002
Filed:

Apr 12, 1999
Appl. No.:

09/289934
Inventors:

Karl Robert Dahnke - Carmel IN
Assignee:

Eli Lilly and Company - Indianapolis IN
International Classification:

C07D50159
US Classification:

514200, 514208, 540215, 540229, 540205, 540301
Abstract:

The invention provides new fluorinated cephalosporin antibiotics of Formula I wherein R , R , R , R and R , independently, are H, F or a C -C alkyl-(Z) â group having at least one fluorine substituent; X is O or S; Y is S, O, or âCH â; Z is O, S, âSOâ, or âSO â; m and n independently are 0 or 1; and R is H, C -C -alkyl, phenyl or benzyl, each of which may optionally have up to three substituents selected from halo, C -C -alkoxy, phenyl, NO , C -C -alkanoyl, benzoyl, or C -C -alkanoyloxy; or a physiologically acceptable salt thereof; and methods of preventing or treating or treating infection, particularly mastitis in ruminants, using these antibiotics.

[4-(Benzo[B]Thiophen-2-Yl) Pyrimidin-2-Yl]-Amine Derivatives As Ikk-Beta Inhibitors For The Treatment Of Cancer And Inflammatory Diseases
view source
US Patent:

7547691, Jun 16, 2009
Filed:

Nov 15, 2006
Appl. No.:

12/093024
Inventors:

Karl Robert Dahnke - Carmel IN, US
Ho-Shen Lin - Indianapolis IN, US
Michael Enrico Richett - Indianapolis IN, US
Chuan Shih - Carmel IN, US
Q May Wang - Indianapolis IN, US
Bo Zhang - Fishers IN, US
Assignee:

Eli Lilly and Company - Indianapolis IN
International Classification:

C07D 409/04
A61K 31/506
US Classification:

514218, 51425214, 514275, 540575, 544295, 544331
Abstract:

The present invention provides compounds of Formula I: useful in the treatment of cancer and inflammatory diseases.

Phenyl-Thiophene Type Vitamin D Receptor Modulators
view source
US Patent:

7601850, Oct 13, 2009
Filed:

May 22, 2003
Appl. No.:

10/515403
Inventors:

Karl Robert Dahnke - Carmel IN, US
Robert Peter Gajewski - Indianapolis IN, US
Charles David Jones - Indianapolis IN, US
Jared Harris Linebarger - Indianapolis IN, US
Jianliang Lu - Fishers IN, US
Tianwei Ma - Carmel IN, US
Sunil Nagpal - Carmel IN, US
Todd Parker Simard - Fishers IN, US
Ying Kwong Yee - Carmel IN, US
Emilio Enrique Bunel - Thousand Oaks CA, US
Ryan Edward Stites - Indianapolis IN, US
Assignee:

Eli Lilly and Company - Indianapolis IN
International Classification:

C07D 333/06
C07D 333/26
US Classification:

549 80
Abstract:

The present invention relates to novel, non-secosteroidal, phenyl-thiophene compounds with vitamin D receptor (VDR) modulating activity that are less hypercalcemic than 1α,25 dihydroxy vitamin D3. These compounds are useful for treating bone disease and psoriasis.

Cephalosporin Antibiotics
view source
US Patent:

63293633, Dec 11, 2001
Filed:

Nov 6, 1998
Appl. No.:

9/188783
Inventors:

Karl Robert Dahnke - Carmel IN
Assignee:

Eli Lilly and Company - Indianapolis IN
International Classification:

C07D50148
C07D50152
A61K 31545
A61P 3104
US Classification:

514204
Abstract:

The invention provides new fluorinated cephalosporin antibiotics and methods of preventing or treating infection, particularly mastitis in ruminants, using these antibiotics, and veterinary and pharmaceutical formulations comprising these antibiotics.

5'-Substituted Nucleoside Compounds
view source
US Patent:

20160326208, Nov 10, 2016
Filed:

Apr 27, 2016
Appl. No.:

15/139370
Inventors:

- Indianapolis IN, US
Karl Robert DAHNKE - Carmel IN, US
Michael John GROGAN - Indianapolis IN, US
Antonio Rodriguez HERGUETA - Madrid, ES
James Andrew JAMISON - Indianapolis IN, US
Brian Morgan WATSON - Carmel IN, US
Timothy Andrew WOODS - Edinburgh IN, US
Zahid Quyoom BONDAY - Carmel IN, US
International Classification:

C07H 19/14
Abstract:

The present invention relates to novel 5′-substituted nucleoside compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds to treat cancer, more particularly for the treatment of cancer, in particular glioblastomas, melanoma, sarcomas, gastric cancer, pancreatic cancer, cholangiocarcinoma, bladder cancer, breast cancer, non-small cell lung cancer, leukemias including acute myeloid leukemia, and lymphomas.

Karl R Dahnke